Lung Cancer News

CHICAGO — Durvalumab conferred significant survival benefits in patients with limited-stage small-cell lung cancer following standard-of-care treatment in a randomized phase 3 trial, according to findings presented at ASCO Annual Meeting.

When Robert A. Winn, MD, learned he’d receive the Allen Lichter Visionary Leader Award at this year’s ASCO Annual Meeting, he reacted in the form of a question: “What just happened?”

CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.

CHICAGO — Early palliative care via telehealth had an equivalent impact on quality of life as in-person visits for patients with advanced non-small cell lung cancer, according to study findings presented at ASCO Annual Meeting.

CHICAGO — Lorlatinib delivered never-before-seen PFS results in adults with anaplastic lymphoma kinase-positive non-small cell lung cancer, according to findings from a randomized phase 3 trial presented at ASCO Annual Meeting.

People who vaped and smoked cigarettes appeared four times more likely to develop lung cancer compared with those who only smoked, according to study results presented at American Association for Cancer Research Annual Meeting.

Certain individuals with non-cell lung cancer who experienced immune-related adverse events due to immune checkpoint inhibitor therapy had improved survival outcomes, according to retrospective study data published in JAMA Network Open.

The FDA granted accelerated approval to tarlatamab-dlle for treatment of certain patients with extensive-stage small cell lung cancer.

Researchers at Keck Medicine of USC launched the first clinical trial to evaluate the feasibility of at-home, subcutaneous immunotherapy treatment for non-small cell lung cancer.

A randomized phase 3 trial that evaluated nivolumab with concurrent chemoradiotherapy for certain patients with advanced lung cancer failed to meet its primary endpoint, according to the agent’s manufacturer.